Method of eliminating hematopoietic stem cells/hematopoietic progenitors (HSC/HP) in a patient using bi-specific antibodies
The described invention provides compositions containing bispecific antibodies that bind to human tyrosine kinase receptor FLT3/FLK2 receptor protein and to CD3 receptor protein expressed on T-cells and use of the compositions containing the bispecific antibodies in the preparation of a medicament for eliminating hematopoietic stem cells/hematopoietic progenitors (HSC/HP) in a patient.
1. A method for preparing or conditioning a patient in need thereof for hematopoietic cell transplantation comprising:
providing a pharmaceutical composition comprising a recombinant single chain bi-specific antibody that binds to both human FLT3 and human CD3, wherein the bi-specific antibody comprises a heavy chain binding domain that binds FLT3 and a light chain binding domain that binds FLT3, wherein the heavy chain binding domain comprises SEQ ID NO: 1, and the light chain binding domain comprises SEQ ID NO: 2, and wherein the bi-specific antibody comprises a monoclonal antibody that reacts with human CD3, and a pharmaceutically acceptable excipient; and
administering a therapeutic amount of the pharmaceutical composition to the patient;
wherein the therapeutic amount is effective:
to reduce by at least 90% a level in peripheral blood of a cell population expressing one or more of CD45, CD3, FLT3, CD19, CD33, and
to reduce toxicity of protocols for preparing or conditioning the patient.
2. The method according to claim 1 , wherein the bi-specific antibody comprises an isotype selected from the group consisting of an immunoglobulin G (IgG), an IgM, an IgE, an IgA, and an IgD isotype.
3. The method according to claim 1 , wherein said therapeutic amount comprises 0.01 mg/kg to 10 mg/kg, better 0.05 mg/kg to 2 mg/kg, better 0.1 mg/kg to 0.5 mg/kg, better 0.1 mg/kg to 0.3 mg/kg, better 0.1 mg/kg.
4. The method according to claim 1 , wherein the patient in need thereof is suffering from acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CLL), CML, peripheral T cell lymphoma, follicular lymphoma, diffuse large B cell lymphoma, Hodgkin lymphoma, non-Hodgkin lymphoma, neuroblastoma, a non-malignant inherited and acquired marrow disorder, multiple myeloma, or SOD.
5. The method according to claim 4 , wherein the non-malignant inherited and acquired marrow disorder is selected from sickle cell anemia, beta-thalassemia major, refractory Diamond-Blackfan anemia, myelodysplastic syndrome, idiopathic severe aplastic anemia, paroxysmal nocturnal hemoglobinuria, pure red cell aplasia, Fanconi anemia, amegakaryocytosis, and congenital thrombocytopenia.
6. The method according to claim 1 , wherein the pharmaceutical composition further comprises an antitumor agent.
7. The method according to claim 1 , wherein the bispecific antibody is a humanized antibody.
8. The method according to claim 1 , wherein the recombinant single chain bi-specific antibody that binds to both human FLT3 and human CD3 comprises a C-terminus of an Fab antigen-binding fragment of an Flt3 monoclonal antibody joined to a CH2 domain of IgG1, and joined to the CH2 domain of the IgG1 a single chain variable fragment (ScFv) of a monoclonal antibody that reacts with a subunit of human CD3 (UCHT1).
9. The method of claim 1 , wherein the subunit of CD3 is UCHT1.
10. A recombinant single chain bi-specific antibody that binds to both human FLT3 and human CD3 comprising:
a C-terminus of an Fab antigen-binding fragment of an Flt3 monoclonal antibody that is joined to a CH2 domain of IgG 1, wherein the recombinant single chain bi-specific antibody comprises a heavy chain binding domain that binds FLT3 and a light chain binding domain that binds FLT3, wherein the heavy chain binding domain comprises SEQ ID NO: 1, and the light chain binding domain is SEQ ID NO: 2; and
a single chain variable fragment (ScFv) of a monoclonal antibody that reacts with a subunit of human CD3 (UCHT1) joined to the CH2 domain of the IgG1.